VRTX241108C290000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals (VRTX) Gets a Buy From Evercore ISI
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $476 to $600
Cautious Hold Rating on Vertex Pharmaceuticals Amid Strong Performance and Limited Upside
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $503 From $510, Maintains Overweight Rating
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS) and Vertex Pharmaceuticals (VRTX)
Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals: Strong Financial Performance and Promising Future Prospects Justify Buy Rating
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Maintains Target Price $361
Vertex Pharmaceuticals Is Maintained at Outperform by Oppenheimer